Allogene Therapeutics Inc

Allogene Therapeutics insider trades reveal routine sell‑to‑cover moves; executive liquidity stays stable while the company advances its CAR‑T pipeline.

Allogene Therapeutics insider trades show routine sell‑to‑cover moves, while massive new options and RSU grants underscore the team’s confidence in its CAR‑T pipeline and long‑term upside.

Allogene Therapeutics insider sell‑to‑cover by R&D EVP is a routine tax move, not a sign of declining confidence; investors see neutral impact and upside potential.